| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Reproductive and Adult Endocrinology Program (H.J.L.M.T., K.P., T.T.H., K.T.A.), Laboratory of Pathology (M.A.A., M.T., M.J.M.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1109; Department of Pathology (B.E.B.), Yale University School of Medicine, New Haven, Connecticut 06510; Department of Endocrinology (H.J.L.M.T.), Radboud University Nijmegen Medical Centre, 9101 6500 HB Nijmegen, The Netherlands; and Institute of Clinical Chemistry and Laboratory Medicine and the Department of Medicine (G.E.), University of Dresden, D-01062 Dresden, Germany
Address all correspondence and requests for reprints to: Henri J. L. M. Timmers, M.D., Ph.D., Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Drive, Building 10, CRC, Room 1-E 3140, Bethesda Maryland 20892-1109. E-mail: h.timmers{at}endo.umcn.nl.
Context: Patients with adrenal and extra-adrenal abdominal paraganglioma (PGL) almost invariably have increased plasma and urine concentrations of metanephrines, the O-methylated metabolites of catecholamines. We report four cases of biochemically silent abdominal PGL, in which metanephrines were normal despite extensive disease.
Objective: Our objective was to identify the mechanism underlying the lack of catecholamine hypersecretion and metabolism to metanephrines in biochemically silent PGL.
Design: This is a descriptive study.
Setting: The study was performed at a referral center.
Patients: One index case and three additional patients with large abdominal PGL and metastases but with the lack of evidence of catecholamine production, six patients with metastatic catecholamine-producing PGL and a mutation of the succinate dehydrogenase subunit B (SDHB) gene, and 136 random patients with catecholamine-producing PGL were included in the study.
Main Outcome Measures: Plasma, urine, and tumor tissue concentrations of catecholamines and metabolites were calculated with electron microscopy and tyrosine hydroxylase immunohistochemistry.
Results: All four patients with biochemically silent PGL had an underlying SDHB mutation. In the index case, the tumor tissue concentration of catecholamines (1.8 nmol/g) was less than 0.01% that of the median (20,410 nmol/g) for the 136 patients with catecholamine-producing tumors. Electron microscopy showed the presence of normal secretory granules in all four biochemically silent PGLs. Tyrosine hydroxylase immunoreactivity was negligible in the four biochemically silent PGLs but abundant in catecholamine-producing PGLs.
Conclusions: Patients with SDHB mutations may present with biochemically silent abdominal PGLs due to defective catecholamine synthesis resulting from the absence of tyrosine hydroxylase. Screening for tumors in patients with SDHB mutations should not be limited to biochemical tests of catecholamine excess.
This article has been cited by other articles:
![]() |
H. J L M Timmers, A.-P. Gimenez-Roqueplo, M. Mannelli, and K. Pacak Clinical aspects of SDHx-related pheochromocytoma and paraganglioma Endocr. Relat. Cancer, June 1, 2009; 16(2): 391 - 400. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |